Original Article

Bone Marrow Transplantation advance online
publication 4 February 2008; doi: 10.1038/bmt.2008.2

Myeloablative therapy with autologous stem cell rescue for
patients with Ewing sarcoma

S L Gardner¹, J Carreras², C Boudreau³, B M Camitta⁴, R H Adams⁵, A R Chen⁶, S M Davies⁷, J R Edwards⁸, A C Grovas⁹, G A Hale¹⁰, H M Lazarus¹¹, M Arora¹², P J Stiff¹³ and M Eapen²

1. ¹Department of Pediatric Oncology, New York
   University, New York, NY, USA
2. ²Statistical
   Center, Center for International Blood and Marrow Transplant Research,
   Medical College of Wisconsin, Milwaukee, WI, USA
3. ³Department of Statistics & Actuarial
   Science, University of Waterloo, Waterloo, Ontario, Canada
4. ⁴Department of Pediatrics, Medical College
   of Wisconsin, Milwaukee, WI, USA
5. ⁵BMT Internal Medicine, Mayo Clinic Arizona,
   Phoenix, AZ, USA
6. ⁶Department of Pediatric Oncology, John
   Hopkins Hospital, Baltimore, MD, USA
7. ⁷Department of Bone Marrow Transplantation,
   Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
8. ⁸Department of Bone Marrow Transplantation,
   Florida Hospital Cancer Institute, Orlando, FL, USA
9. ⁹Department of Pediatrics, University of
   Nebraska Medical Center, Omaha, NE, USA
10. ¹⁰Department of Bone Marrow
    Transplantation, St Jude Children's Research Hospital, Memphis, TN, USA
11. ¹¹Department of Hematology/Oncology,
    University Hospitals of Cleveland, Cleveland, OH, USA
12. ¹²Department of Hematology/Oncology,
    University of Minnesota, Minneapolis, MN, USA
13. ¹³Department of Bone Marrow
    Transplantation, Loyola University Medical Center, Maywood, IL, USA

Correspondence:
Dr M Eapen, Statistical Center, Center for International Blood and
Marrow Transplant Research, Medical College of Wisconsin, 8701
Watertown Plank Road, Milwaukee, WI 53226, USA. E-mail: meapen@mcw.edu

Received 20 August 2007; Revised 19 December 2007;
Accepted 20 December 2007; Published online 4 February 2008.

The aim of this study was to identify risk factors
associated with PFS in patients with Ewing sarcoma undergoing ASCT; 116
patients underwent ASCT in 1989–2000 and reported to the Center for
International Blood and Marrow Transplant Research. Eighty patients
(69%) received ASCT as first-line therapy and 36 (31%), for recurrent
disease. Risk factors affecting ASCT were analyzed with use of the Cox
regression method. Metastatic disease at diagnosis, recurrence prior to
ASCT and performance score <90 were associated with higher rates of
disease recurrence/progression. Five-year probabilities of PFS in
patients with localized and metastatic disease at diagnosis who
received ASCT as first-line therapy were 49% (95% CI 30–69) and 34%
(95% CI 22–47) respectively. The 5-year probability of PFS in patients
with localized disease at diagnosis, and received ASCT after recurrence
was 14% (95% CI 3–30). PFS rates after ASCT are comparable to published
rates in patients with similar disease characteristics treated with
conventional chemotherapy, surgery and irradiation suggesting a limited
role for ASCT in these patients. Therefore, ASCT if considered should
be for high-risk patients in the setting of carefully controlled
clinical trials.